See the Full Picture.
Published loading...Updated

GLP-1 prescriptions for weight loss are shooting up, despite obstacles

  • GLP-1 drug prescriptions for overweight and obese adults in the US increased sharply from 0.3% in 2019 to 2.05% in 2024, based on commercial claims data.
  • This rise occurred amid longstanding obesity challenges and limited treatment access, with over 80% of patients lacking GLP-1 drugs, surgery, or behavioral care in 2024.
  • Three GLP-1 drugs—Saxenda, Wegovy, and Zepbound—are FDA-approved for weight management, with Novo Nordisk and Eli Lilly leading sales but facing supply and market competition issues.
  • Novo Nordisk reported $9.9 billion and Eli Lilly $4.9 billion in 2024 GLP-1 sales, while the increasing prescriptions coincided with falling bariatric surgery and behavioral health service rates.
  • These trends suggest GLP-1 drugs may be replacing other obesity treatments, raising concerns about access, safety of compounded versions, and implications for healthcare stakeholders.
Insights by Ground AI
Does this summary seem wrong?

12 Articles

All
Left
1
Center
2
Right
4
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 57% of the sources lean Right
57% Right
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

healthcaredive.com broke the news in on Wednesday, May 28, 2025.
Sources are mostly out of (0)